AQST Aquestive Therapeutics Inc
Price (delayed)
$2.64
Market cap
$261.02M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.51
Enterprise value
$311.33M
Aquestive Therapeutics is a pharmaceutical company that applies innovative technology to solve therapeutic problems and improve medicines for patients. The Company has commercialized one internally-developed proprietary product to date, Sympazan,
Highlights
Aquestive Therapeutics's gross margin has increased by 17% YoY
Aquestive Therapeutics's quick ratio has surged by 136% YoY but it has decreased by 28% QoQ
AQST's equity is up by 44% year-on-year but it is down by 32% since the previous quarter
AQST's net income is down by 25% since the previous quarter
The EPS has declined by 11% since the previous quarter
Key stats
What are the main financial stats of AQST
Market
Valuations
Earnings
Shares outstanding
98.87M
Market cap
$261.02M
Enterprise value
$311.33M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
3.98
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.41
Revenue
$57.56M
Gross profit
$39.69M
Operating income
-$30.77M
Net income
-$44.14M
EBIT
-$27.33M
EBITDA
-$26.62M
Free cash flow
-$35.92M
Per share
Balance sheet
Liquidity
EPS
-$0.51
EPS diluted
-$0.51
Free cash flow per share
-$0.41
Book value per share
-$0.66
Revenue per share
$0.66
TBVPS
$1.17
Total assets
$101.42M
Total liabilities
$161.58M
Debt
$121.85M
Equity
-$60.16M
Working capital
$69.36M
Debt to equity
-2.03
Current ratio
4.68
Quick ratio
4.18
Net debt/EBITDA
-1.89
Margins
Efficiency
Dividend
EBITDA margin
-46.2%
Gross margin
69%
Net margin
-76.7%
Operating margin
-53.5%
Return on assets
-38.5%
Return on equity
N/A
Return on invested capital
-20.6%
Return on capital employed
-33.1%
Return on sales
-47.5%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
AQST stock price
How has the Aquestive Therapeutics stock price performed over time
Intraday
3.94%
1 week
-3.3%
1 month
-11.11%
1 year
-46.56%
YTD
-25.84%
QTD
-25.84%
Financial performance
How have Aquestive Therapeutics's revenue and profit performed over time
Revenue
$57.56M
Gross profit
$39.69M
Operating income
-$30.77M
Net income
-$44.14M
Gross margin
69%
Net margin
-76.7%
The operating income has plunged by 104% YoY and by 46% from the previous quarter
Aquestive Therapeutics's operating margin has shrunk by 79% YoY and by 49% QoQ
The company's gross profit rose by 33% YoY but it fell by 2.9% QoQ
The net margin has contracted by 28% from the previous quarter
Growth
What is Aquestive Therapeutics's growth rate over time
Valuation
What is Aquestive Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
3.98
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.41
The EPS has declined by 11% since the previous quarter
AQST's equity is up by 44% year-on-year but it is down by 32% since the previous quarter
AQST's P/S is 31% below its last 4 quarters average of 5.8 but 28% above its 5-year quarterly average of 3.1
Aquestive Therapeutics's revenue has increased by 14% YoY but it has decreased by 2.3% from the previous quarter
Efficiency
How efficient is Aquestive Therapeutics business performance
AQST's ROA has dropped by 187% year-on-year and by 13% since the previous quarter
The return on sales has declined by 45% since the previous quarter
The company's return on invested capital fell by 40% QoQ
Dividends
What is AQST's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for AQST.
Financial health
How did Aquestive Therapeutics financials performed over time
The company's total assets is 37% lower than its total liabilities
Aquestive Therapeutics's quick ratio has surged by 136% YoY but it has decreased by 28% QoQ
The current ratio has surged by 109% year-on-year but it has declined by 27% since the previous quarter
AQST's debt to equity has dropped by 92% year-on-year but it is up by 23% since the previous quarter
AQST's equity is up by 44% year-on-year but it is down by 32% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.